GILD and KYMR Related Headlines
Go Back- Bernstein on US Pharma and Biotech: Who might buy whom?
- Gilead exercises option for Kymera's cancer drug candidate KT-200
- Where can biotech stocks go from here? RBC answers
- Kymera’s partnerships with Sanofi and Gilead drive value
- Kymera Therapeutics (KYMR) PT Lowered to $64 at Jefferies
- Gilead Sciences (GILD) and Kymera Therapeutics (KYMR) Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
- Gilead Sciences and Kymera Therapeutics Enter Into Exclusive Option and License Agreement to Develop Novel Oral Molecular Glue CDK2 Degraders
